H
Hiroshi Nishihara
Researcher at Keio University
Publications - 677
Citations - 17201
Hiroshi Nishihara is an academic researcher from Keio University. The author has contributed to research in topics: Medicine & Terpyridine. The author has an hindex of 62, co-authored 616 publications receiving 14683 citations. Previous affiliations of Hiroshi Nishihara include Tokyo University of Science & Ochanomizu University.
Papers
More filters
Journal ArticleDOI
First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion
Kazunori Shojo,Takeo Kosaka,Kohei Nakamura,Hiroshi Hongo,Hiroaki Kobayashi,Shuji Mikami,Hiroshi Nishihara,Mototsugu Oya +7 more
TL;DR: Ductal adenocarcinoma of the prostate is a rare prostate cancer variant and associated with higher stage and greater risk of mortality and optimal systemic therapy is not known.
Journal ArticleDOI
Electron-Beam Writing Fabrication of Periodic Structure for Quasi-Phase-Matching Second-Harmonic Generation in Dimethyl Nitrophenyl Pyrazole Crystal Waveguide
TL;DR: In this article, a periodic structure for quasi-phase matching (QPM) second-harmonic generation (SHG) in 3,5-dimethyl-1-(4-nitrophenyl) pyrazole (DMNP) by electron-beam (EB) writing was demonstrated.
Journal ArticleDOI
Clinical predominance of whole‐exome sequencing to evaluate microsatellite instability status
Reika Takamatsu,Kohei Nakamura,Okihide Suzuki,Chihiro Okada,Ryo Mori,Hideyuki Hayashi,Marin Ishikawa,Eriko Aimono,Sachio Nohara,Shigeki Tanishima,Arisa Ueki,Hideyuki Ishida,Hiroshi Nishihara +12 more
TL;DR: In this article , the concordance among the MSIsensor score obtained from whole-exome sequencing (WES), which could be a futuristic clinical cancer sequencing method, using only tumor tissues, MSI-PCR results, and immunohistochemistry (IHC) results to analyze various solid cancer types.
Journal ArticleDOI
CW Laser Oscillation in Z-Cut Nd-Diffused Ti:MgO:LiNbO3 Waveguides
TL;DR: In this article, a prototype waveguide laser of 14mm long was fabricated, and CW oscillation was achieved at a wavelength of 1085 nm by optical pumping at 809 nm.
Journal Article
[Crosstalk of Cancer Genomic Test and Cancer Immune Therapy].
TL;DR: The conventional MSI test is consist of direct PCR method to amplify the microsatellite region using DNA derived from tumor specimen as a companion diagnostic for pembrolizumab CDx, while the recent comprehensive genomic profiling test such as FoundationOne CDx also evaluate the MSI status.